Literature DB >> 16019715

The double jeopardy of HDL.

Mohamad Navab1, G M Ananthramaiah, Srinivasa T Reddy, Brian J Van Lenten, Benjamin J Ansell, Susan Hama, Greg Hough, Eugene Bachini, Victor R Grijalva, Alan C Wagner, Zory Shaposhnik, Alan M Fogelman.   

Abstract

The ability of high-density lipoprotein (HDL) to promote cholesterol efflux is thought to be important in its protection against cardiovascular disease. Anti-inflammatory properties of HDL have emerged as additional properties that may also be important. HDL appears to have evolved as part of the innate immune system functioning to inhibit inflammation in the absence of an acute phase response (APR) but functioning to increase inflammation in the presence of an APR. Inbred strains of mice that are genetically susceptible to atherosclerosis have pro-inflammatory HDL, while inbred strains that are resistant to atherosclerosis have anti-inflammatory HDL. In one small study, humans with coronary heart disease (CHD) or CHD equivalents had pro-inflammatory HDL prior to statin therapy and about half continued to have pro-inflammatory HDL after statin therapy despite a profound decrease in plasma lipids. Pro-inflammatory HDL was relatively weak in its ability to promote cholesterol efflux while anti-inflammatory HDL was better in promoting cholesterol efflux. In other studies, oxidative alterations of the major protein of HDL, apolipoprotein A-I (apoA-I), impaired the ability of the apoA-I to promote cholesterol efflux. Thus, HDL structure and function may be more important than HDL-cholesterol levels in predicting risk for cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16019715     DOI: 10.1080/07853890510007322

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  46 in total

1.  Can we learn more about the etiology of cardiovascular disease?

Authors:  Lewis H Kuller
Journal:  Eur J Epidemiol       Date:  2007-02-28       Impact factor: 8.082

2.  Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma.

Authors:  Liang Wang; Pei-dong Chi; Hao Chen; Jin Xiang; Zhong-jun Xia; Yu-jing Zhang
Journal:  Tumour Biol       Date:  2014-03

Review 3.  The role of dysfunctional HDL in atherosclerosis.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2008-10-27       Impact factor: 5.922

4.  Coronary artery diseases in South Asian immigrants: an update on high density lipoprotein role in disease prevention.

Authors:  Sunita Dodani
Journal:  J Immigr Minor Health       Date:  2008-09-24

5.  Association Between Low-Grade Systemic Inflammation and Type 2 Diabetes Mellitus Among Men and Women from the ATTICA Study.

Authors:  Christos Pitsavos; Metaxia Tampourlou; Demosthenes B Panagiotakos; Yannis Skoumas; Christina Chrysohoou; Tzortzis Nomikos; Christodoulos Stefanadis
Journal:  Rev Diabet Stud       Date:  2007-08-10

6.  Atherothrombosis in South asians: implications of atherosclerotic and inflammatory markers.

Authors:  Sunita Dodani
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

7.  Methodological constraints in interpreting serum paraoxonase-1 activity measurements: an example from a study in HIV-infected patients.

Authors:  Sandra Parra; Judit Marsillach; Gerard Aragonès; Anna Rull; Raúl Beltrán-Debón; Carlos Alonso-Villaverde; Jorge Joven; Jordi Camps
Journal:  Lipids Health Dis       Date:  2010-03-25       Impact factor: 3.876

Review 8.  High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; Georgette M Buga; Greg Hough; Alan C Wagner; Alan M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11       Impact factor: 8.311

9.  Is elevated high-density lipoprotein cholesterol always good for coronary heart disease?

Authors:  Yuhua Sun; Yuejin Yang; Weidong Pei; Yongjian Wu; Jinglin Zhao
Journal:  Clin Cardiol       Date:  2007-11       Impact factor: 2.882

Review 10.  HDL as a biomarker, potential therapeutic target, and therapy.

Authors:  Mohamad Navab; G M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Alan M Fogelman
Journal:  Diabetes       Date:  2009-12       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.